A retrospective assessment of the use of naltrexone implants for the treatment of problematic amphetamine use

American Journal on Addictions

Volumn 22, Issue 1, 2013, Pages 1-6

  Kelty, Erin ^a,b   Thomson, Karen ^a   Carlstein, Sarah ^a   Sinclair, Rebecca ^a   Hulse, Gary ^b  

^a Fresh Start Recovery Programme   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; BENZODIAZEPINE; CANNABIS; CIGARETTE SMOKE; COCAINE; NALTREXONE; OPIATE;

ABSTINENCE; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ABUSE; LETHARGY; MALE; METHAMPHETAMINE DEPENDENCE; PAIN; SELF REPORT; SMOKING; SUSTAINED DRUG RELEASE; SWELLING; TREATMENT DURATION; URINALYSIS; VOMITING;

ADULT; AMPHETAMINE-RELATED DISORDERS; DRUG IMPLANTS; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RETROSPECTIVE STUDIES; SELF REPORT;

EID: 84873674974     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.00320.x     Document Type: Article

References (32)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report. Vienna: United Nations; 2009.
2. Jayaram-Lindstrom N, Wennberg P, Beck O, et al. An open clinical trial of naltrexone for amphetamine dependence: Compliance and tolerability. Nordic J Psychiatry. 2005; 59: 167-171.
3. Jayaram-Lindstrom N, Hammarberg A, Beck O, et al. Naltrexone for the treatment of amphetamine dependence: A randomised, placebo-controlled trial. Am J Psychiatry. 2008; 165: 1442-1448.
4. Hulse GK, Basso MR., The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000; 19: 41-48.
5. Azatian A, Papiasvilli A, Joseph H., A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J Addict Dis. 1994; 13: 35-52.
6. Tennant FS Jr, Rawson RA, Cohen AJ, et al. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry. 1984; 45: 42-45.
7. Krupitsky EM, Blokhina EA., Long-acting depot formulations of naltrexone for heroin dependence: A review. Curr Opin Psychiatry. 2010; 23: 210-214.
8. Alkermes I., Vivitrol: Naltrexone for extended-release injectable suspension. 2007; [cited 2008 2nd November 2008 Full Prescribing Information]. Available from: http://www.vivitrol.com/hcp/Vivitrol-Info/adverse-effects- safety.aspx.
9. Kranzler HR, Wesson DR, Billot L., Naltrexone depot for treatment of alcohol dependence: A multicentre, randomised placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004; 28: 1051-1059.
10. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex(R)) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004; 9: 1356-1361.
11. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomised control trial. J Am Med Assoc. 2005; 293: 1617-1625.
12. Hulse G, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: Randomized controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009; 66: 1108-1115.
13. Hulse GK, Low VH, Stalenberg V, et al. Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humans. Addict Biol. 2007; 13: 364-372.
14. Hulse GK, Stalenberg V, McCallum D, et al. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release. 2005; 108: 43-55.
15. Jayaram-Lindstrom N., Evaluation of naltrexone as a treatment for amphetamine dependence. (Thesis.) Department of Clinical Neurosciences. Karolinska Institutet, Stockholm, 2007.
16. Hulse GK, Arnold-Reed DE, O'Neil G, et al. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: Comparing two naltrexone implants. Addict Biol. 2004; 9: 59-65.
17. Ngo HTT, Arnold-Reed DE, Hansson RC, et al. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 23-28.
18. Bugge CJL, Grun I, Stanfor K, et al. Determination of naltrexone, 6-beta-naltrexol in human plasma by LC-MS-MS. Austin, Texas: CEDRA Corporation; 1996.
19. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry. 2006; 63: 210-218.
20. Latt NC, Jurd S, Houseman J, et al. Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002; 176: 530-534.
21. O'Malley SS, Garbutt JC, Gastfriend DR, et al. Efficacy of extended-release naltrexone in alcohol-dependent patients whose are abstinent before treatment. J Clin Psychopharmacol. 2007; 27: 507-512.
22. Brewer C., Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases. Addict Biol. 2002; 7: 321-323.
23. Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: Long lasting antagonism of the effects of heroin in humans. Psychopharmacology. 2002; 159: 351-360.
24. Haney M, Bisaga A, Foltin RW., Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology. 2003; 166: 77-85.
25. Haney M., Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007; 32: 1391-1403.
26. Swift R, Davidson D, Rosen S, et al. Naltrexone effects on diazepam intoxication and pharmacokinetics in humans. Psychopharmacology. 1998; 135: 256-262.
27. Rukstalis M, Jepson C, Strasser A, et al. Naltrexone reduced the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacologica. 2005; 180: 41-48.
28. Cramer CM, Hubbell CL, Reid LD., A combination of isradipine and naltrexone blocks cocaine's enhancement of a cocaine place preference. Pharmacol Biochem Behav. 1998; 60: 847-853.
29. Dykstra LA, Doty P, Johnson AB, et al. Discriminative stimulus properties of cocaine, alone and in combination with buprenorphine, morphine and naltrexone. Drug Alcohol Depend. 1992; 30: 227-234.
30. Epstein AM, King A., Naltrexone attenuates acute cigarette smoking behaviour. Pharmacol Biochem Behav. 2004; 77: 29-37.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association; 2000.
32. MIMS Australia. MIMS. St Leonards, NSW: CMP Medical Australia Pty Ltd; 2005.